Tirzepatide is the active ingredient in Zepbound and Mounjaro, and the trial results behind it are strong [1]. Compounded tirzepatide is a pharmacy-made copy of that molecule. The trials discussed here did not evaluate the pharmacy preparation proposed to an individual patient; compounded drugs do not undergo FDA premarket review of safety, effectiveness or quality [8]. So the honest answer to “does it work?” has two halves: the molecule does, and whether your vial delivers it is a separate question.
Tirzepatide works: the trial numbers
In the main weight trial, weekly tirzepatide produced 15.0%, 19.5% and 20.9% average weight loss at 5, 10 and 15 mg, against 3.1% on placebo, after 72 weeks [1]. That study enrolled adults with obesity or overweight who didn’t have type 2 diabetes.
Two more trials fill in the picture. In SURMOUNT-5, tirzepatide 10 or 15 mg exceeded semaglutide 1.7 or 2.4 mg in an open-label comparison of 751 adults with obesity without diabetes: 20.2% weight loss against 13.7% at 72 weeks [2]. In the open-label SURPASS-2 trial of 1,879 people with type 2 diabetes saw their A1C fall by 2.01 to 2.30 percentage points over 40 weeks, more than on semaglutide 1 mg [4]. All three were funded by Lilly and used Lilly’s manufactured drug.
The controlled-trial evidence does not establish compounded-product equivalence
Every number above comes from Lilly’s drug. The cited controlled trials do not establish equivalence between a compounded tirzepatide preparation and Zepbound. The market survey and laboratory paper below examine other questions; neither supplies that clinical comparison.
A 2025 opinion from a pharmacist group at the American College of Clinical Pharmacy put it plainly. It found “limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide” [5]. The same group urged prescribers to help patients get approved drugs where they can, and to monitor anyone on a compounded one.
FDA’s own position is the reason the gap matters. Compounded drugs “are not FDA approved,” which means the agency “does not review compounded drugs for safety, effectiveness or quality before they are marketed” [8].
| Question | Tested on approved tirzepatide? | Tested on compounded tirzepatide? | Source |
|---|---|---|---|
| Weight loss vs placebo | Yes: 15.0% to 20.9% at 72 weeks | Not established by the cited controlled trials | SURMOUNT-1 [1] |
| Weight loss vs semaglutide | Yes: 20.2% vs 13.7% | Not established by the cited controlled trials | SURMOUNT-5 [2] |
| Blood sugar in type 2 diabetes | Yes: A1C down 2.01 to 2.30 points | Not established by the cited controlled trials | SURPASS-2 [4] |
| Moderate to severe obstructive sleep apnea in adults with obesity | Yes: Zepbound has this specific indication | Not established by the cited controlled trials | Zepbound label [9] |
| Weight kept off with continued use | Yes: a further 5.5% lost from week 36 to 88 | Not established by the cited controlled trials | SURMOUNT-4 [3] |
| Regain after stopping | Yes: 14.0% regained on placebo | Not established by the cited controlled trials | SURMOUNT-4 [3] |
| Clinical outcomes in practice | Not applicable | Small groups of patients only | ACCP opinion, 2025 [5] |
The table describes the cited evidence, not an exhaustive claim that no other research exists. Trial results remain specific to the studied formulation, population and design.
Same molecule doesn’t guarantee the same result
Ingredient identity, labeled strength, storage and correct use matter, but matching those features does not demonstrate that a compounded preparation reproduces a trial result. Formulation, impurities, stability and clinical performance also need evidence. FDA identifies several risks to examine without implying that a checklist can certify equivalence.
| Risk | What FDA or a study reported | What you can check |
|---|---|---|
| Strength not verified | FDA doesn’t review compounded drugs for quality before sale [8] | Ask which licensed pharmacy makes it |
| Doses beyond the label | FDA has adverse-event reports tied to compounded doses beyond the approved label, or raised faster [8] | Ask your prescriber how your dose compares with the label |
| Add-ins such as B12 | Lilly scientists reported a new tirzepatide–B12 impurity in mass-compounded products; its clinical effects are unknown [6] | Ask whether your product is plain tirzepatide |
| Warm delivery | FDA advises against using any injectable GLP-1 that arrives warm [8] | Check that it ships cold |
| Unlicensed supplier | 4 of 21 supplier facilities in a 2026 study weren’t licensed for sterile compounding [7] | Ask for the pharmacy’s name and license |
The B12 impurity paper’s authors list Eli Lilly affiliations. Lilly makes Zepbound and Mounjaro; the analytical study did not measure clinical outcomes or establish how often patients are harmed.
The dosing point deserves a second look. FDA describes adverse events in people prescribed compounded tirzepatide “in doses beyond what is in the FDA-approved drug label,” which “could mean using more product in a single dose, taking doses more frequently or increasing the amount more quickly” [8]. A product that’s dosed differently from the trials can’t borrow the trials’ results.
Add-ins are the other common gap. In a 2026 secret-shopper study of clinics and med spas in two states, 56.0% offered a GLP-1 with B vitamins [7]. The studies cited here do not establish that adding B12 or glycine improves weight loss.
Does the cited evidence establish equal effectiveness?
The studies cited here do not establish equivalent clinical outcomes between compounded tirzepatide and Zepbound or Mounjaro. That uncertainty is not evidence of equality, superiority or inferiority for a particular vial. A plausible ingredient name does not resolve the missing comparison. The compounded tirzepatide vs Zepbound comparison covers price, form and access side by side.
Ask the prescriber how response will be assessed
Agree on the monitoring plan with the clinician rather than interpreting a short-term weight or appetite change as a product test. Zepbound’s label starts every patient at 2.5 mg, a dose meant to begin treatment rather than to keep you on, and allows up to 15 mg a week [9]. A label escalation schedule does not establish an individual response deadline or validate a compounded product’s potency.
Discuss unexpected response, troublesome side effects or concerns about the package with the prescriber and pharmacist. These observations alone cannot identify a dosing, formulation, handling or clinical cause, and the cited sources do not establish their relative likelihoods. Don’t change your dose on your own; the label sets the dose ranges for the approved drug, and your prescriber sets yours.
The withdrawal trial found average regain after switching to placebo
SURMOUNT-4 enrolled 783 adults without diabetes in a 36-week open-label lead-in; 670 completers were randomized to continued treatment or placebo for 52 weeks. Average change from randomization to week 88 was 14.0% regain on placebo versus a further 5.5% loss with continued tirzepatide [3]. At week 88, mean weight remained 9.9% below original baseline in the placebo group versus 25.3% below in the continued-treatment group. The selected completer population and studied formulation limit extrapolation to every person or compounded preparation. Discuss long-term planning with the clinician.
Questions for the prescriber and dispensing pharmacist
Ask which pharmacy location will prepare the prescription, what ingredients it contains and what evidence supports the exact formulation. A public network name is a starting point for checking a license, not proof of sterility, potency or clinical equivalence. The pharmacy checklist helps organize these questions, and the appointment guide helps prepare the treatment discussion.
- Ask which pharmacy compounds it, and check that it’s licensed in your state.
- Ask whether the product is plain tirzepatide or carries an add-in.
- Confirm it ships with cold packs, and don’t use a dose that arrives warm.
- Ask how your dose compares with the approved label.
- Make sure a licensed clinician is available after your medicine arrives.
For the risks side of this decision, read is compounded tirzepatide safe. For where things stand legally, see is compounded tirzepatide still available. Prices are in compounded tirzepatide cost, and the where to get compounded tirzepatide guide walks through the options. 23 telehealth programs on this site prescribe tirzepatide, compared on the compounded tirzepatide scores. The same evidence question for semaglutide is answered in does compounded semaglutide work, and the molecule itself is explained on the tirzepatide page.